Core Insights - Resmed Inc. reported a strong start to fiscal year 2026, with a 9% year-over-year revenue growth and significant improvements in gross margins and earnings per share [2][3][5] Financial Performance - Revenue for the quarter ended September 30, 2025, was $1,335.6 million, up from $1,224.5 million in the same quarter of 2024, reflecting a 9% increase [4][5][21] - Non-GAAP gross margin improved by 280 basis points to 62.0%, while GAAP gross margin increased by 290 basis points to 61.5% [5][21] - Non-GAAP diluted earnings per share rose by 16% to $2.55, compared to $2.20 in the prior year [5][19] Operational Highlights - Income from operations increased by 15% to $446.5 million, with non-GAAP income from operations rising by 19% to $482.1 million [5][19] - Operating cash flow for the quarter was $457 million, indicating strong cash generation capabilities [5][17] - The company declared a quarterly cash dividend of $0.60 per share, payable on December 18, 2025 [8] Market and Product Insights - Revenue growth was driven by increased demand for sleep devices, masks, and accessories, with U.S., Canada, and Latin America revenue growing by 10% [9][21] - The company launched the Sleep Institute to promote sleep health as a public health priority and published a study projecting a significant increase in obstructive sleep apnea cases by 2050 [9][11] Strategic Initiatives - Resmed is committed to ongoing operational excellence and strategic investments in innovation to ensure sustainable growth [4][9] - The company recorded $16 million in restructuring-related charges as part of workforce planning aligned with its 2030 strategic priorities [9]

Core Insights - WORK Medical Technology Group Ltd. is exploring real-world asset (RWA) tokenization and blockchain technology through a partnership with the Hong Kong Web3.0 Standardization Association, aiming to leverage its existing product infrastructure and AI business [3][4][11] - The company has outlined three main areas for collaboration: tokenization of high-quality assets, equity investments, and development of RWA technology [6][7][9] Company Strategy - The partnership aligns with WORK Medical's "Healthcare + Payment + Technology = RWA + Web3 + AI" strategy, which aims to integrate various sectors for growth [4] - The company plans to collaborate with qualified firms in the financial sector to ensure compliance in its asset tokenization efforts [4] Market Potential - Tokenized RWAs are projected to exceed $50 billion by the end of the year, with U.S. treasuries expected to dominate this market, contributing over $28 billion [5] Collaboration Areas - The first area of collaboration focuses on tokenizing high-quality assets owned or invested in by WORK Medical, potentially including receivables, investment products, and intellectual property [6] - The second area involves equity investments, which may include co-investments or participation in funds to accelerate RWA tokenization [7] - The third area is the development of RWA technology, utilizing the Hong Kong Web3.0 Association's RWA registration platform for regulatory compliance and asset security [9] Recent Developments - WORK Medical has also formed a partnership with Ruijin Hospital's Wuxi Branch to advance AI-driven healthcare solutions, integrating multimodal medical data [12][13] - The company's revenue from its mask business fell 69% to $1.6 million, while revenue from other medical devices increased by 18% to $9.4 million [16] - The company generated $400,000 from commodities trading and $15.7 million from financing activities in its latest fiscal year [17]